Abstract
Renal cell carcinoma (RCC) is a common malignancy. Surgery is the standard of care for primary RCC; however, many patients in this population are elderly or have so severe medical comorbidities that they cannot be operated, and partial nephrectomy of patients with only one kidney may result in chronic kidney disease. Stereotactic body radiotherapy (SBRT) is widely used as a treatment method in which high local control can be obtained with minimal invasiveness, and it is often reported that high local control can be safely obtained even for renal cancer. Some techniques and results of SBRT for RCC will be presented and discussed here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
NCCN Clinical Practice Guidelines in Oncology Kidney Cancer Version 4.2022 https://www.nccn.org/home
Ning S, Trisler K, Wessels BW, et al. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80(12 Suppl):2519–28.
Law AW, Mole RH. Direct and abscopal effects of x-radiation on the thymus of the weanling rat. Int J Radiat Biol Relat Stud Phys Chem Med. 1961;3:233–48.
Wersäll PJ, Blomgren H, Pisa P, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45:493–7.
Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced Abscopal effect. Cancer Immunol Res. 2015;3:610–9.
Onishi H, Kawakami H, Marino K, et al. A simple respiratory indicator for irradiation during voluntary breath holding: a one-touch device without electronic materials. Radiology. 2010;255:917–23.
Onishi H, Kuriyama K, Komiyama T, et al. A new irradiation system for lung cancer combining linear accelerator, computed tomography, patient self-breath-holding, and patient-directed beam-control without respiratory monitoring devices. Int J Radiat Oncol Biol Phys. 2003;56:14–20.
Siva S, Ellis RJ, Ponsky L, et al. Consensus statement from the international radiosurgery oncology consortium for kidney for primary renal cell carcinoma. Future Oncol. 2016;12:637–45.
Siva S, Chesson B, Bressel M, et al. TROG 15.03 phase II clinical trial of focal ablative Stereotactic radiosurgery for cancers of the kidney—FASTRACK II. BMC Cancer. 2018;18(1):1030.
Hasegawa T, Takaki H, Miyagi H, et al. Cardiovasc Intervent Radiol. 2013;36(4):1144–6.
Onishi H, Kawasaki T, Zakoji H, et al. Renal cell carcinoma treated with stereotactic radiotherapy with histological change confirmed on autopsy: a case report. BMC Res Notes. 2014;26(7):270.
Shuto T, Inomori S, Fujino H, at al. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. J Neurosurg. 2006;105:555–60.
Svedman C, Sandström P, Pisa P, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870–5.
Svedman C, Karlsson K, Rutkowska E, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47:1578–83.
Beitler JJ, Makara D, Silverman P, et al. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27(6):646–8.
Teh B, Bloch C, Galli-Guevara M. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J. 2007;3(1):e6.
Funayama S, Onishi H, Kuriyama K, et al. Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy. Technol Cancer Res Treat. 2019;18:1533033818822329.
Staehler M, Bader M, Schlenker B, et al. Single fraction radiosurgery for the treatment of renal tumors. J Urol. 2015;193:771–5.
Siva S, Pham D, Gill S, et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E737–43.
Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the international radiosurgery oncology consortium for kidney (IROCK). Cancer. 2018;124:934–42.
Correa RJM, Louie AV, Zaorskyet NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019;5(6):958–69.
Uhlig A, Uhlig J, Trojanet L, et al. Stereotactic body radiotherapy for stage I renal cell carcinoma: National Treatment Trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol. 2020;31(4):564–71.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Onishi, H. (2023). Kidney. In: Nagata, Y. (eds) Stereotactic Body Radiation Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-99-3978-7_12
Download citation
DOI: https://doi.org/10.1007/978-981-99-3978-7_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-3977-0
Online ISBN: 978-981-99-3978-7
eBook Packages: MedicineMedicine (R0)